COHEN & STEERS INC (CNS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock
63.99 USD
-0.21 (-0.33%)
63.99 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to CNS. CNS was compared to 235 industry peers in the Capital Markets industry. CNS has an excellent profitability rating, but there are some minor concerns on its financial health. CNS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CNS was profitable.
In the past year CNS has reported a negative cash flow from operations.
Each year in the past 5 years CNS has been profitable.
CNS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CNS has a better Return On Assets (20.48%) than 97.87% of its industry peers.
With an excellent Return On Equity value of 29.83%, CNS belongs to the best of the industry, outperforming 95.74% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 24.24%, CNS belongs to the top of the industry, outperforming 98.30% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for CNS is significantly above the industry average of 7.07%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(24.24%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROIC | 24.24% |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
1.3 Margins
With a decent Profit Margin value of 29.73%, CNS is doing good in the industry, outperforming 75.74% of the companies in the same industry.
In the last couple of years the Profit Margin of CNS has declined.
CNS has a better Operating Margin (33.83%) than 65.53% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
The Gross Margin of CNS (88.60%) is better than 92.77% of its industry peers.
In the last couple of years the Gross Margin of CNS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% |
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
2. Health
2.1 Basic Checks
Compared to 1 year ago, CNS has more shares outstanding
The number of shares outstanding for CNS has been increased compared to 5 years ago.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 9.02 indicates that CNS is not in any danger for bankruptcy at the moment.
CNS has a Altman-Z score of 9.02. This is amongst the best in the industry. CNS outperforms 93.19% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.02 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CNS (0.79) is worse than 63.83% of its industry peers.
CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a worse Quick ratio (0.79) than 63.40% of its industry peers.
The current and quick ratio evaluation for CNS is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
CNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.87%, which is quite good.
Measured over the past 5 years, CNS shows a small growth in Earnings Per Share. The EPS has been growing by 2.50% on average per year.
CNS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.13%.
Measured over the past years, CNS shows a small growth in Revenue. The Revenue has been growing by 4.72% on average per year.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
3.2 Future
CNS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.
CNS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.21% yearly.
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CNS is valuated rather expensively with a Price/Earnings ratio of 20.84.
The rest of the industry has a similar Price/Earnings ratio as CNS.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (26.84), we can say CNS is valued slightly cheaper.
The Price/Forward Earnings ratio is 18.60, which indicates a rather expensive current valuation of CNS.
CNS's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.40, CNS is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.84 | ||
| Fwd PE | 18.6 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CNS is valued a bit cheaper than 79.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 16.02 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CNS has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)4.57
PEG (5Y)8.35
EPS Next 2Y8.37%
EPS Next 3Y8.1%
5. Dividend
5.1 Amount
CNS has a Yearly Dividend Yield of 3.92%.
Compared to an average industry Dividend Yield of 6.65, CNS has a dividend in line with its industry peers.
CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.92% |
5.2 History
The dividend of CNS decreases each year by -7.12%.
CNS has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
63.99
-0.21 (-0.33%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners58.72%
Inst Owner Change-5.95%
Ins Owners22.81%
Ins Owner Change3.3%
Market Cap3.26B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target78.54 (22.74%)
Short Float %6.45%
Short Ratio4.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.92% |
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.35%
PT rev (3m)-1.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.87%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)2.7%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.84 | ||
| Fwd PE | 18.6 | ||
| P/S | 5.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.93 | ||
| P/tB | 6.16 | ||
| EV/EBITDA | 16.02 |
EPS(TTM)3.07
EY4.8%
EPS(NY)3.44
Fwd EY5.38%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)4.57
PEG (5Y)8.35
Graham Number27.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.48% | ||
| ROE | 29.83% | ||
| ROCE | 31.59% | ||
| ROIC | 24.24% | ||
| ROICexc | 29.06% | ||
| ROICexgc | 32.58% | ||
| OM | 33.83% | ||
| PM (TTM) | 29.73% | ||
| GM | 88.6% | ||
| FCFM | N/A |
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 1.34% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.79 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 9.02 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year11.2%
EBIT Next 3Y14.28%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%
COHEN & STEERS INC / CNS FAQ
What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?
ChartMill assigns a fundamental rating of 6 / 10 to CNS.
Can you provide the valuation status for COHEN & STEERS INC?
ChartMill assigns a valuation rating of 3 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.
Can you provide the profitability details for COHEN & STEERS INC?
COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.
What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?
The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 20.84 and the Price/Book (PB) ratio is 5.93.
What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?
The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.